Gyre Therapeutics (GYRE) Total Debt (2010 - 2014)
Gyre Therapeutics (GYRE) posted quarterly Total Debt of $478000.0 for Q3 2014, down 64.62% year-over-year from $1.4 million in Q3 2013, and down 31.62% quarter-over-quarter from $699000.0 in Q2 2014.
Gyre Therapeutics (GYRE) Total Debt (2010 - 2014) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Total Debt for 5 consecutive years, with $478000.0 the latest figure, recorded in Q3 2014.
- In Q3 2014, Total Debt fell 64.62% year-over-year to $478000.0; the TTM figure through Sep 2014 stood at $478000.0 (down 64.62% YoY), while the FY2013 annual figure was $1.1 million, down 42.83% from the prior year.
- Total Debt eased to $478000.0 in Q3 2014 per GYRE's latest filing, from $699000.0 in the prior quarter.
- Across five years, Total Debt topped out at $4.3 million in Q2 2011 and bottomed at $478000.0 in Q3 2014.
- Historically, Total Debt has averaged $2.1 million across 5 years, with a median of $2.0 million in 2012.
- Annual changes were most pronounced in 2011 — Total Debt rose 5.49% — and 2014, when it tumbled 64.62%.
- Gyre Therapeutics' Total Debt stood at $3.1 million in 2010, then advanced by 5.49% to $3.2 million in 2011, then plunged by 38.43% to $2.0 million in 2012, then plunged by 42.83% to $1.1 million in 2013, then sank by 57.92% to $478000.0 in 2014.
- Business Quant data shows GYRE's Total Debt at $478000.0 in Q3 2014, $699000.0 in Q2 2014, and $918000.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 478,000.00 |
| Jun 30, 2014 | 699,000.00 |
| Mar 31, 2014 | 918,000.00 |
| Dec 31, 2013 | 1.14 Mn |
| Sep 30, 2013 | 1.35 Mn |
| Jun 30, 2013 | 1.57 Mn |
| Mar 31, 2013 | 1.78 Mn |
| Dec 31, 2012 | 1.99 Mn |
| Sep 30, 2012 | 2.20 Mn |
| Jun 30, 2012 | 2.43 Mn |
| Mar 31, 2012 | 2.67 Mn |
| Dec 31, 2011 | 3.23 Mn |
| Sep 30, 2011 | 3.79 Mn |
| Jun 30, 2011 | 4.35 Mn |
| Dec 31, 2010 | 3.06 Mn |